ALKERMES PLC (ALKS) Stock Price, Quote, News and Overview
NASDAQ:ALKS - Nasdaq - IE00B56GVS15 - Common Stock - Currency: USD
ALKS Quote, Performance and Key Statistics
ALKERMES PLC
NASDAQ:ALKS (2/4/2025, 8:26:11 PM)
After market: 31.28 -0.02 (-0.06%)31.3
+0.54 (+1.76%)
The current stock price of ALKS is 31.3 USD. In the past month the price increased by 7.78%. In the past year, price increased by 14.57%.
ALKS Latest News, Press Releases and Analysis
NASDAQ:ALKS is a prime example of a stock that offers more than what meets the eye in terms of fundamentals.
When you look at ALKERMES PLC (NASDAQ:ALKS), it's hard to ignore the strong fundamentals, especially considering its likely undervaluation.
Alkermes to Present at the 43rd Annual J.P. Morgan Healthcare Conference
/PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) announced today that its Chief Executive Officer, Richard Pops, will provide a corporate overview and update at the...
Alkermes to Participate in Upcoming Investor Conferences
/PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) announced today that management will participate in two upcoming investor conferences. 7th Annual Evercore ISI...
Alkermes to Participate in Two Upcoming Investor Conferences
/PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) announced today that management will participate at two upcoming investor conferences. Stifel Healthcare Conference...
ALKS Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 18.77 | 335.67B | ||
| AMGN | AMGEN INC | 15.04 | 155.36B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 945.65 | 124.20B | ||
| GILD | GILEAD SCIENCES INC | 22.12 | 122.12B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.34 | 76.60B | ||
| ARGX | ARGENX SE - ADR | N/A | 38.95B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 34.95B | ||
| BNTX | BIONTECH SE-ADR | N/A | 28.08B | ||
| ONC | BEIGENE LTD-ADR | N/A | 23.76B | ||
| NTRA | NATERA INC | N/A | 23.00B | ||
| BIIB | BIOGEN INC | 8.73 | 20.76B | ||
| UTHR | UNITED THERAPEUTICS CORP | 15.52 | 15.78B |
Related stock screener links
About ALKS
Company Profile
Alkermes Plc is a global biopharmaceutical company, which engages in the business of developing, manufacturing, and commercializing medicines designed to address unmet medical needs of patients in major therapeutic areas such as alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder, and a pipeline of product candidates in development for neurological disorders and cancer. The company is headquartered in Dublin, Dublin and currently employs 2,100 full-time employees. The firm has a portfolio of commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical candidates in development for neurological disorders. The company focuses on commercial products, such as LYBALVI, ARISTADA/ARISTADA INITIO and VIVITROL, and advancing the development of pipeline programs focused on neurological disorders. LYBALVI is a once-daily, oral atypical antipsychotic drug for the treatment of adults with schizophrenia and for the treatment of adults with bipolar I disorder, as a maintenance monotherapy or for the acute treatment of manic or mixed episodes, as monotherapy or an adjunct to lithium or valproate. ARISTADA is an extended-release intramuscular injectable suspension for the treatment of schizophrenia. The company has a manufacturing facility in Wilmington, Ohio.
Company Info
ALKERMES PLC
Connaught House, 1 Burlington Road, Dublin 4
DUBLIN DUBLIN DUBLIN 4 IE
CEO: Richard F. Pops
Employees: 2100
Company Website: https://www.alkermes.com/
Investor Relations: https://investor.alkermes.com
Phone: 35317728000
ALKS FAQ
What is the stock price of ALKS?
The current stock price of ALKS is 31.3 USD.
What is the symbol for ALKERMES PLC stock?
The exchange symbol of ALKERMES PLC is ALKS and it is listed on the Nasdaq exchange.
On which exchange is ALKS stock listed?
ALKS stock is listed on the Nasdaq exchange.
Is ALKS a good stock to buy?
Always make your own analysis. On these pages you can find a full technical and fundamental analysis report for ALKS, which may be a starting point for your analysis. You can also find the financials, news, analyst ratings and estimates here, which can be used to increase your understanding of ALKS.
Does ALKS stock pay dividends?
ALKS does not pay a dividend.
When does ALKS stock report earnings?
ALKS will report earnings on 2025-02-13, after the market close.
What is the Price/Earnings (PE) ratio of ALKS?
The PE ratio for ALKS is 15.12. This is based on the reported non-GAAP earnings per share of 2.07 and the current share price of 31.3 USD.
What is the Short Interest ratio of ALKS stock?
The outstanding short interest for ALKS is 7.16% of its float.
ALKS Technical Analysis
ChartMill assigns a technical rating of 9 / 10 to ALKS. When comparing the yearly performance of all stocks, ALKS is one of the better performing stocks in the market, outperforming 75.8% of all stocks.
ALKS Fundamental Analysis
ChartMill assigns a fundamental rating of 6 / 10 to ALKS. While ALKS has a great health rating, its profitability is only average at the moment.
ALKS Financial Highlights
Over the last trailing twelve months ALKS reported a non-GAAP Earnings per Share(EPS) of 2.07. The EPS increased by 54.48% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 22.15% | ||
| ROA | 15.47% | ||
| ROE | 25.8% | ||
| Debt/Equity | 0.22 |
ALKS Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 78% to ALKS. The Buy consensus is the average rating of analysts ratings from 20 analysts.
For the next year, analysts expect an EPS growth of 91.65% and a revenue growth -8.56% for ALKS